Auberger Jutta, Loeffler-Ragg Judith, Wurzer Walter, Hilbe Wolfgang
Department of Internal Medicine, Division of Hematology and Oncology, Medical University Innsbruck, Austria.
Curr Cancer Drug Targets. 2006 Jun;6(4):271-94. doi: 10.2174/156800906777441780.
Targeted therapies focus on signaling pathways in cancer cells and other molecular processes involved in oncogenesis. Recent approaches affect the following major groups: the epidermal growth factor receptor (EGFR)-family, angiogenesis, the eicosanoid pathway, the PKC/ Ras/ MAPK pathway, the proteasome and inducers of apoptosis. Numerous phase I and II trials have provided promising results and recently, anti-EGFR and anti-VEGF treatments have proven their efficacy in phase III trials. However, others failed in phase III settings (e.g. PKC- and matrix metalloproteinase inhibitors) and it is a moot point, whether patients have been selected properly. The huge amount of new medications raises questions like when to use which strategy in which sequence. The successful implementation of targeted agents into clinical routine will depend on the verification of sufficient predictive markers, allowing their economically reasonable usage. In the current review the up-to-date knowledge concerning targeted therapies in NSCLC is summarized and their therapeutical potential is discussed.
靶向治疗聚焦于癌细胞中的信号通路以及肿瘤发生过程中涉及的其他分子过程。近期的方法影响以下主要类别：表皮生长因子受体（EGFR）家族、血管生成、类花生酸途径、蛋白激酶C/ Ras/丝裂原活化蛋白激酶（MAPK）途径、蛋白酶体和凋亡诱导剂。众多I期和II期试验已取得了有前景的结果，最近，抗EGFR和抗血管内皮生长因子（VEGF）治疗在III期试验中证实了其疗效。然而，其他一些治疗方法在III期试验中失败了（例如蛋白激酶C和基质金属蛋白酶抑制剂），患者是否被正确选择仍是一个有争议的问题。大量新药物引发了诸如何时以何种顺序使用哪种策略等问题。将靶向药物成功应用于临床常规将取决于对足够的预测标志物的验证，以实现其经济合理的使用。在当前综述中，总结了关于非小细胞肺癌（NSCLC）靶向治疗的最新知识，并讨论了它们的治疗潜力。
